Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The Plain Prescription Prices Act directs the HHS Secretary, through the CMS Administrator, to issue regulations within one year requiring direct-to-consumer television advertisements for prescription drugs and biological products (covered by Medicare or Medicaid) to include a truthful, non-misleading textual statement of the drug's list price as of the first day of the quarter for a typical 30-day regimen or course of treatment. The Administrator is also tasked with determining whether to extend requirements to other forms of advertising, specifying the format and manner of the price statement, setting enforcement mechanisms, and deciding whether additional price information should be included.
Whether listing the 'list price' is a meaningful, useful disclosure for consumers (liberal/centrist see some value; conservatives see it as misleading).
Relative to its intended legislative type, this bill clearly creates a new substantive regulatory obligation and appropriately assigns implementation responsibility to the CMS Administrator with a one-year rulemaking deadline.
The Plain Prescription Prices Act directs the HHS Secretary, through the CMS Administrator, to issue regulations within one year requiring direct-to-consumer television advertisements for prescription drugs and biological products (covered by Medicare or Medicaid) to include a truthful, non-misleading textual statement of the drug's list price as of the first day of the quarter for a typical 30-day regimen or course of treatment.
The Administrator is also tasked with determining whether to extend requirements to other forms of advertising, specifying the format and manner of the price statement, setting enforcement mechanisms, and deciding whether additional price information should be included.
On content alone, the bill is narrowly focused and administratively oriented, which helps prospects. However, it addresses a high-profile industry (pharmaceuticals) with well-resourced opposition, raises potential First Amendment and interagency/legal frictions, and lacks funding or clear enforcement mechanics in the statute. Those factors make passage as a standalone measure uncertain unless folded into a larger package or significantly amended.
Relative to its intended legislative type, this bill clearly creates a new substantive regulatory obligation and appropriately assigns implementation responsibility to the CMS Administrator with a one-year rulemaking deadline. It prescribes key substantive elements (applicability to TV ads, requirement for truthful list-price textual statements, quarterly price determination, and target treatment duration) while delegating significant technical and enforcement details to agency rulemaking.
Whether listing the 'list price' is a meaningful, useful disclosure for consumers (liberal/centrist see some value; conservatives see it as misleading).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether listing the 'list price' is a meaningful, useful disclosure for consumers (liberal/centrist see some value; conservatives see it as misleading).
A mainstream progressive would likely view this bill positively as a consumer-protection and price-transparency measure aimed at holding pharmaceutical companies accountable and helping patients understand costs.
They would see it as a useful step toward demystifying drug pricing in a sector where list prices are often opaque.
However, they would note that listing only the list price could be insufficient because many patients face lower out-of-pocket costs due to insurance, discounts, or assistance programs; thus they would press for stronger, more consumer-centered disclosure.
A pragmatic moderate would be cautiously supportive of improved price transparency while emphasizing careful implementation to avoid consumer confusion and undue regulatory burden.
They would appreciate the bill's limited, time-bound directive for CMS to promulgate rules rather than overly prescriptive language, but would be concerned about how 'list price' is defined and presented and whether the measure will actually help consumers.
They would favor piloting clear formatting standards, strong consumer testing, and cost-benefit analysis before broader expansion to other media.
A mainstream conservative would be skeptical of a federal mandate forcing specific price statements in private-sector advertising and likely view the bill as an example of regulatory overreach that burdens speech and commerce.
They would question whether listing a 'list price' serves consumers when insurance, rebates, and coupons often determine actual patient costs.
They would also worry about added compliance costs for manufacturers and broadcasters and prefer market-based or state-level approaches rather than new federal advertising requirements.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is narrowly focused and administratively oriented, which helps prospects. However, it addresses a high-profile industry (pharmaceuticals) with well-resourced opposition, raises potential First Amendment and interagency/legal frictions, and lacks funding or clear enforcement mechanics in the statute. Those factors make passage as a standalone measure uncertain unless folded into a larger package or significantly amended.
The bill has not accumulated any surfaced votes yet.
Whether listing the 'list price' is a meaningful, useful disclosure for consumers (liberal/centrist see some value; conservatives see it as…
On content alone, the bill is narrowly focused and administratively oriented, which helps prospects. However, it addresses a high-profile i…
Relative to its intended legislative type, this bill clearly creates a new substantive regulatory obligation and appropriately assigns implementation responsibility to the CMS Administrator with a one-year rulemaking de…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.